-
Start Preamble
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 2, 2008, Siemens Healthcare Diagnostics Inc., 100 GBC Drive, Mail Stop 514, Newark, Delaware 19702, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:
Drug Schedule Tetrahydrocannabinols (7370) I Ecgonine (9180) II Morphine (9300) II The company plans to produce the listed controlled substances in bulk to be used in the manufacture of reagents and drug calibrator/controls which are DEA exempt products.
Any other such applicant and any person who is presently registered with DEA to manufacture such substances Start Printed Page 9593may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 21, 2008.
Start SignatureDated: February 13, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E8-3175 Filed 2-20-08; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 02/21/2008
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- E8-3175
- Pages:
- 9592-9593 (2 pages)
- PDF File:
- e8-3175.pdf